SCHEMBL3323323

SCHEMBL3323323

COC(=O)C1=C(C)NC2=C(C(=O)CC(c3ccc(OC)c(OC)c3)C2)C1c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
USP2 O75604 2/20 0.63
MAPK1 P28482 1/20 0.63
RAB9A P51151 1/20 0.63
POLB P06746 6/20 0.54
KDM4E B2RXH2 4/20 0.54
CASP1 P29466 2/20 0.54
HSD17B10 Q99714 2/20 0.54
TSHR P16473 1/20 0.54
CASP7 P55210 1/20 0.54
GAA P10253 7/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 4/20 0.52
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5329147 0.90 ALDH1A1 (0.62) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5480584 0.87 ALDH1A1 (0.60) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5333309 0.84 KDM4E (0.66) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL17501858 0.83 ALDH1A1 (0.59) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5471439 0.82 ALDH1A1 (0.60) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5332856 0.81 ALDH1A1 (0.74) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL3323563 0.81 GAA (0.57) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5341434 0.81 GAA (0.67) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL12541319 0.80 ALDH1A1 (0.58) ALDH1A1USP2MAPK1RAB9APOLB
SCHEMBL5477271 0.80 ALDH1A1 (0.65) ALDH1A1USP2MAPK1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 ALDH1A1 2615/4885USP2 1355/4885MAPK1 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.